[Pharmacokinetic interactions of telaprevir with other drugs]

Abstract

Telaprevir is a new direct-acting antiviral drug for the treatment of hepatitis C virus (HCV) infection and is both a substrate and an inhibitor of cytochrome P450 (CYP450) isoenzymes. With the introduction of this new drug, assessment of drug-drug interactions has become a key factor in the evaluation of patients under treatment for HCV infection. During the treatment of this infection, many patients require other drugs to mitigate the adverse effects of anti-HCV drugs and to control other comorbidities. Moreover, most patients coinfected with HIV and HCV require antiretroviral therapy during treatment for HCV. Physicians should therefore be familiar with the pharmacokinetic properties of direct-acting antivirals for HCV treatment and their potential drug-drug interactions. The present article reviews the available information to date on the interactions of telaprevir with other drugs and provides recommendations for daily clinical practice.

Keywords: Antiretroviral drugs; Antirretrovirales; HIV; Hepatitis C; Human immunodeficiency virus; Interacción farmacocinética; Pharmacokinetic interactions; Telaprevir; VIH; Virus de la inmunodeficiencia humana.